376 results on '"Le Garff-Tavernier, Magali"'
Search Results
2. Progressive multifocal leukoencephalopathy in patients with chronic liver disease successfully treated with pembrolizumab
3. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod
4. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
5. Chemotherapy is an efficient treatment in primary CNS MALT lymphoma
6. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network
7. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma
8. Prognostic Value of CSF IL-10 at Early Assessment of Induction Chemotherapy in Primary CNS Lymphomas: A LOC Network Study.
9. Progressive multifocal leukoencephalopathy in patients with chronic liver disease successfully treated with pembrolizumab
10. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod
11. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
12. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53
13. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1–derived peptides overcomes drug resistance
14. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
15. Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease
16. Analysis of cerebrospinal fluid for the diagnosis of CNS lymphoma: Comparison of the ESCCA/ISCCA protocol and real‐world data of the CytHem/LOC French network.
17. Flow cytometry in chronic lymphproliferative disorders: report of a survey on practices on behalf of CytHem
18. Analysis of cerebrospinal fluid for the diagnosis of CNSlymphoma: Comparison of the ESCCA/ISCCAprotocol and real‐world data of the CytHem/LOCFrench network
19. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study
20. CombiningMYD88 L265Pmutation detection and clonality determination on CSF cellular and cell‐free DNA improves diagnosis of primary CNS lymphoma
21. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
22. AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
23. Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
24. A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
25. Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network
26. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
27. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
28. Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study
29. “Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain
30. Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell‐free DNA improves diagnosis of primary CNS lymphoma.
31. Place de l'immunophénotypage dans les syndromes lymphoprolifératifs chroniques : enquête sur les pratiques au sein du CytHem.
32. Diagnostic intégratif des lymphomes primitifs du système nerveux central (LPSNC) dans le LCR par cytologie, cytométrie de flux, MYD88 et IL-10/6
33. Prevalence of IGLV3-21R110 among familial CLL: a retrospective study of 45 cases
34. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network
35. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
36. Evaluation of Paroxysmal Nocturnal Hemoglobinuria Screening by Flow Cytometry Through Multicentric Interlaboratory Comparison in Four Countries
37. Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up
38. A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
39. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
40. Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study
41. Lymphome cérébral sous présentation de démence rapidement progressive : n’oubliez pas les Interleukines !
42. Apport du profil cytokinique des interleukines 6 et 10 dans le LCR et de la biopsie cutanée dans le diagnostic précoce d’un lymphome intravasculaire (LIV) se présentant sous la forme d’une myélite subaiguë
43. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
44. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving and MYC and TP53
45. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
46. Watch out for a second train
47. Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia
48. Persistence of CD16 +/CD56 −/2B4 + natural killer cells: A highly dysfunctional NK subset expanded in ocular myasthenia gravis
49. Lymphome cérébral sous présentation de démence rapidement progressive : n’oubliez pas les Interleukines !
50. Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.